Literature DB >> 27509126

Assessment of Minimal Residual Disease in Standard-Risk AML.

Sarah Morin-Zorman1, Aline Renneville2, Lionel Adès3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27509126     DOI： 10.1056/NEJMc1603847

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Authors:  S Herold; K Sockel; C Sayehli; R Herbst; U Dührsen; U Oelschlägel; A Böttner; H Hindahl; J Kullmer; S Helas; M Sauer; B Mohr; A Mies; M Bornhäuser; G Ehninger; C Röllig; C Thiede; U Platzbecker
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

2.  Exome analysis of treatment-related AML after APL suggests secondary evolution.

Authors:  Tianjiao Wang; Meagan A Jacoby; Eric J Duncavage; Christopher A Miller; Sharon Heath; Ramy Rahme; Pierre Fenaux; Lionel Ades; Aline Renneville; Bruno Cassinat; Akihiro Takeshita; Norio Asou; Yasushi Miyazaki; Hitoshi Kiyoi; Farhad Ravandi; Peter Westervelt; Lukas D Wartman; John S Welch
Journal:  Br J Haematol       Date:  2018-11-22       Impact factor: 6.998

3.  NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Authors:  Alexander Höllein; Manja Meggendorfer; Frank Dicker; Sabine Jeromin; Niroshan Nadarajah; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Blood Adv       Date:  2018-11-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.